Family office Omnia Global to support healthtech company Scandiags

ScanDiags, an AI company with an innovative software platform for medical imaging, partners with Omnia Global. The Zug-based family office will support ScanDiags with business development, financing, and market development activities over the coming year.

ScanDiags' ImagoPlus platform enables the active interpretation of magnetic resonance imaging (MRI) through immediate data detection, quantification, and clinical insight. The platform provides standardized diagnostic reports in a fully automated process that unburdens clinicians at the point of care, increases workflow capacity, and reduces healthcare system costs. Compatible with all MRI hardware platforms, ScanDiags' ImagoPlus platform integrates seamlessly into existing radiology operations.

Omnia Global will support ScanDiags as it continues to focus on the development of its ImagoPlus platform, ongoing product validation and verification, and the pursuit of regulatory clearance from the US Food and Drug Administration (FDA). Omnia Global is an entrepreneurial family office founded by Daniel Hansen, a Danish serial entrepreneur living in Switzerland.

The ImagoPlus Musculoskeletal (MSK) Suite is fully operational and will launch with the Lumbar Spine module; Knee, Shoulder, and Hip modules are being finalized for successive launches over the next year. The company is also expanding the ImagoPlus platform to incorporate Neurological and Cardiovascular pathology suites already in development.

Clinical trials and validation study

"ScanDiags' technology continues to prove itself in the field of radiology," says Tajkarim Mohamed, Director of ScanDiags Health Technologies Inc. "The team has now completed four successful clinical trials in Switzerland, with results published in leading European medical journals. Our validation study in the United States will be finalized later this month as part of the preparation for our 510k submission. These trials and studies have proven our platform's clinical accuracy and diagnostic effectiveness, and we anticipate a successful FDA clearance by mid-year."

"OMNIA works with entrepreneurs to develop and grow their businesses and expedite the rate at which their innovative products and offerings reach public markets," says Daniel Hansen, OMNIA Global's CEO. "ScanDiags has developed a unique product that will ultimately give doctors more time to spend with their patients, and we are excited to work with the company to realise their strategic financing and commercialization objectives over the coming year."

The development of the ScanDiags product was initiated in 2015 by founder René Balzano and his team of seasoned data scientists and software engineers at Balzano Informatik AG in Zurich, Switzerland. The company was later renamed to ScanDiags AG. Today, the Research and Development group, ScanDiags AG, is based in Zurich whereas ScanDiags Health Technologies Inc. is headquartered in Vancouver, Canada.

(Press release / SK)